Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.
Details on Person Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action
| Class:Id | LiteratureReference:9691593 |
|---|---|
| _displayName | Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action |
| _timestamp | 2020-06-18 13:33:13 |
| author | [Person:9691627] Sheridan, Douglas [Person:9691617] Yu, Zhao-Xue [Person:9691595] Zhang, Yuchun [Person:9691620] Patel, Rekha [Person:9691625] Sun, Fang [Person:9691610] Lasaro, Melissa A [Person:9691618] Bouchard, Keith [Person:9691628] Andrien, Bruce [Person:9691615] Marozsan, Andre [Person:9691626] Wang, Yi [Person:9691619] Tamburini, Paul |
| created | [InstanceEdit:9691596] Jassal, Bijay, 2020-06-18 |
| journal | PLoS ONE |
| pages | e0195909 |
| pubMedIdentifier | 29649283 |
| title | Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action |
| volume | 13 |
| year | 2018 |
| (literatureReference) | [Summation:9691612] Activation of the complement system significantly contribute... [Reaction:9691621] C5 binds C5 inhibitors [Homo sapiens] |
| [Change default viewing format] | |
No pathways have been reviewed or authored by Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action (9691593)
